TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the stock.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of TherapeuticsMD in a report on Thursday, August 17th.

TherapeuticsMD Stock Down 1.1 %

NASDAQ:TXMD opened at $3.60 on Friday. TherapeuticsMD has a 12 month low of $3.25 and a 12 month high of $9.03. The company has a 50 day simple moving average of $3.95 and a two-hundred day simple moving average of $3.88.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.17). TherapeuticsMD had a net margin of 61.23% and a return on equity of 232.35%. The business had revenue of $0.44 million for the quarter. As a group, equities analysts forecast that TherapeuticsMD will post -0.75 earnings per share for the current year.

Institutional Trading of TherapeuticsMD

Hedge funds have recently made changes to their positions in the business. State Street Corp raised its position in TherapeuticsMD by 0.3% in the 1st quarter. State Street Corp now owns 7,259,095 shares of the company’s stock worth $2,758,000 after purchasing an additional 19,452 shares during the period. Renaissance Technologies LLC lifted its position in TherapeuticsMD by 243.5% during the first quarter. Renaissance Technologies LLC now owns 3,147,599 shares of the company’s stock valued at $1,196,000 after acquiring an additional 2,231,301 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in TherapeuticsMD by 727.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,860,361 shares of the company’s stock valued at $1,087,000 after acquiring an additional 2,514,618 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of TherapeuticsMD by 688.1% in the first quarter. Royal Bank of Canada now owns 788,446 shares of the company’s stock worth $299,000 after buying an additional 688,399 shares during the last quarter. Finally, Clearline Capital LP raised its holdings in shares of TherapeuticsMD by 8.6% in the second quarter. Clearline Capital LP now owns 455,372 shares of the company’s stock worth $1,876,000 after buying an additional 35,947 shares during the last quarter. 28.68% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.